Turner NC, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19. https://doi.org/10.1056/nejmoa1505270.

Article  CAS  PubMed  Google Scholar 

Finn RS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36. https://doi.org/10.1056/nejmoa1607303.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. https://doi.org/10.1056/nejmoa1609709.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–72. https://doi.org/10.1200/JCO.2018.78.9909.

Article  CAS  PubMed  Google Scholar 

Tripathy D, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15. https://doi.org/10.1016/S1470-2045(18)30292-4.

Article  CAS  PubMed  Google Scholar 

Sledge GW, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84. https://doi.org/10.1200/JCO.2017.73.7585.

Article  CAS  PubMed  Google Scholar 

Goetz MP, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46. https://doi.org/10.1200/JCO.2017.75.6155.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50. https://doi.org/10.1056/nejmoa2114663.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–24. https://doi.org/10.1056/nejmoa1911149.

Article  CAS  PubMed  Google Scholar 

Im S-A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–16. https://doi.org/10.1056/nejmoa1903765.

Article  CAS  PubMed  Google Scholar 

Sledge GW, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116. https://doi.org/10.1001/jamaoncol.2019.4782.

Article  PubMed  Google Scholar 

Goetz MP et al. MONARCH 3: final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer. San Antonio Breast Cancer Symposium. p. Abstract GS01–12. 2023.

Finn RS, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): analyses. J Clin Oncol. 2022;40(17_suppl):LBA1003. https://doi.org/10.1200/jco.2022.40.17_suppl.lba1003.

Article  Google Scholar 

Turner NC, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36. https://doi.org/10.1056/nejmoa1810527.

Article  CAS  PubMed  Google Scholar 

Sonke GS, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017–03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol. 2023;41(17_suppl):LBA1000. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA1000.

Article  Google Scholar 

Johnston SRD, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–98. https://doi.org/10.1200/JCO.20.02514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slamon DJ, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: primary results from the phase III NATALEE trial. J Clin Oncol. 2023;41(17_suppl):LBA500. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA500.

Article  Google Scholar 

Harbour JW, et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98(6):859–69. https://doi.org/10.1016/S0092-8674(00)81519-6.

Article  CAS  PubMed  Google Scholar 

Nurse PM. Nobel lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep. 2002;22(5–6):487–99. https://doi.org/10.1023/a:1022017701871. (England).

Article  CAS  PubMed  Google Scholar 

Goel S, Bergholz JS, Zhao JJ. Targeting cyclin-dependent kinases 4 and 6 in cancer. Nat Rev Cancer. 2022;22(6):356. https://doi.org/10.1038/s41568-022-00456-3.Targeting.

Article  CAS  PubMed  PubMed Central  Google Scholar 

George MA, et al. Clinical and pharmacologic differences of CDK4/6 inhibitors in breast cancer. Front Oncol. 2021;11. https://doi.org/10.3389/fonc.2021.693104.

Hafner M, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26(8):1067-1080.e8. https://doi.org/10.1016/j.chembiol.2019.05.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickler MN, et al. Monarch 1. Clin Cancer Res. 2017;23(17):5218–24. https://doi.org/10.1158/1078-0432.CCR-17-0754.MONARCH.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471–5. https://doi.org/10.1038/nature23465.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schaer DA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978–94. https://doi.org/10.1016/j.celrep.2018.02.053.

Article  CAS  PubMed  Google Scholar 

Deng J, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216–33. https://doi.org/10.1158/2159-8290.CD-17-0915.

Article  CAS  PubMed  Google Scholar 

Lelliott EJ, et al. CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memory. Cancer Discov. 2021;11(10):2582–601. https://doi.org/10.1158/2159-8290.CD-20-1554.

Article  CAS  PubMed  Google Scholar 

Asghar US, et al. Systematic review of molecular biomarkers predictive of resistance to CDK4/6 inhibition in metastatic breast cancer. JCO Precis Oncol. 2022;6:1–13. https://doi.org/10.1200/po.21.00002.

Article  Google Scholar 

Formisano L, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1–14. https://doi.org/10.1038/s41467-019-09068-2.

Article  CAS  Google Scholar 

Nayar U, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies. Nat Genet. 2019;51(2):207–16. https://doi.org/10.1038/s41588-018-0287-5.

Article  CAS  PubMed  Google Scholar 

Yang C, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36(16):2255–64. https://doi.org/10.1038/onc.2016.379.